Protagonist Therapeutics, Inc. (PTGX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -48.94M | -36.98M | -1.94M | -28.78M | 125.36M | -29.18M | -27.86M | 268.62M | -27.43M | 16.96M | -26.61M | -26.24M |
| Operating CF Margin % | - | -497.18% | -41.11% | -518.93% | 442.65% | -17.1% | -596% | 6446.41% | -10.76% | 28.27% | - | - |
| Operating CF Growth % | -139.04% | -26.72% | 93.05% | -110.71% | 557.05% | -272.04% | -4.7% | 1123.79% | 20.14% | 153.61% | -5.59% | -92.43% |
| Net Income | 3.78M | 85.77M | -39.34M | -34.77M | -11.65M | 131.67M | -33.21M | -30.62M | 207.34M | 27.34M | -34.1M | -38.46M |
| Depreciation & Amortization | 407K | -904K | 361K | 304K | 239K | 536K | 647K | 892K | 820K | 832K | 827K | 821K |
| Stock-Based Compensation | 14.52M | 10.7M | 0 | 10.91M | 13.8M | 9.09M | 10.16M | 0 | 0 | 6.6M | 6.76M | 8.34M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -67.65M | -129.87M | 8.98M | -1.35M | -1.72M | -2.76M | -2.84M | 7.28M | 7.74M | -1.35M | -1.01M | -960K |
| Working Capital Changes | 0 | -2.67M | 28.06M | -3.88M | 124.69M | -167.72M | -2.63M | 291.06M | -243.33M | -16.46M | 908K | 4.02M |
| Change in Receivables | 0 | 462K | -583K | 538K | 165M | -165M | 43K | 300M | -290.04M | -10M | 39K | 12K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12K |
| Change in Payables | 3M | -307K | 2.42M | 375K | 1.24M | -1.43M | -355K | -201K | 2.83M | -597K | -3.2M | 552K |
| Cash from Investing | 90.89M | 48.81M | -58.55M | 54.81M | -94.4M | -8.72M | -208.71M | -88.12M | 6.07M | -61.29M | -13.56M | 25.76M |
| Capital Expenditures | -215K | 1.45M | -88K | -813K | -545K | -310K | -775K | -28K | -242K | -19K | -404K | -176K |
| CapEx % of Revenue | - | 19.44% | 1.87% | 14.66% | 1.92% | 0.18% | 16.58% | 0.67% | 0.09% | 0.03% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25.94M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -49.32M | 0 | -5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.94M |
| Cash from Financing | 23.37M | 2.84M | 5.66M | 2.92M | 11.44M | 4.03M | 12.05M | 2.57M | 7.2M | 527K | 35.31M | 108.17M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 2.84M | 5.66M | 2.92M | 11.92M | 0 | 12.05M | 2.57M | 7.8M | 8K | -78K | 107.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 23.37M | 0 | 0 | 0 | -479K | 4.03M | 0 | 0 | -600K | 519K | 35.39M | 304K |
| Net Change in Cash | 65.32M | 14.68M | -54.83M | 28.95M | 42.4M | -33.87M | -224.52M | 183.07M | -14.16M | -43.8M | -4.86M | 107.7M |
| Free Cash Flow | -49.16M | -35.53M | -2.02M | -29.59M | 124.82M | -29.49M | -28.64M | 268.59M | -27.67M | 16.94M | -27.02M | -26.41M |
| FCF Margin % | - | -477.73% | -42.98% | -533.59% | 440.73% | -17.28% | -612.58% | 6445.74% | -10.85% | 28.23% | - | - |
| FCF Growth % | -139.38% | -20.49% | 92.93% | -111.02% | 551.08% | -274.06% | -6.01% | 1116.86% | 19.46% | 153.43% | -6.51% | -89.69% |
| FCF per Share | -0.70 | -0.56 | -0.03 | -0.47 | 1.98 | -0.44 | -0.46 | 4.38 | -0.44 | 0.27 | -0.46 | -0.47 |
| FCF Conversion (FCF/Net Income) | -12.94x | 0.83x | 0.05x | 0.83x | -10.76x | -0.22x | 0.84x | -8.77x | -0.13x | 0.62x | 0.78x | 0.68x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |